Biotech Values

[DewDiligence]

MNTA:

Is there a change in the financial terms for 2 vs 3 companies getting approval?

Whether there are two approved generics or three approved generics makes no difference in the formula used to calculate MNTA’s royalties, but a third generic would presumably reduce NVS’ sales on which MNTA’s royalties are based.

Given what we may infer about Amphastar’s application from the fact that WPI is unprepared for launch, the distinction in the above paragraph is probably of theoretical interest only :- )